Abstract. Colorectal cancer (CRC) is the third leading cause of cancer-associated mortality, and is a major health problem. Collagen type I α 1 (COL1A1) is a major component of collagen type I. Recently, it was reported to be overexpressed in a variety of tumor tissues and cells. However, the function of COL1A1 in CRC remains unclear. Herein, the present study demonstrated that COL1A1 was upregulated in CRC tissues and the paired lymph node tissues. Transwell assays showed that COL1A1 promoted CRC cell migration in vitro. Moreover, it was revealed that COL1A1 levels were correlated with those of WNT/planar cell polarity (PCP) signaling pathway genes; inhibition of COL1A1 decreased the expression levels of Ras-related C3 botulinum toxin substrate 1-GTP, phosphorylated-c-Jun N-terminal kinase, and RhoA-GTP, all of which are key genes in the WNT/PCP signaling pathway. These results may indicate the mechanisms underlying the oncogenic role of COL1A1 in CRC. In summary, the present data indicated that COL1A1 may serve as an oncoprotein, and that it may be used as a potential therapeutic target in CRC.
Introduction
Colorectal cancer (CRC) is a common malignant tumor of the digestive system (1) . In recent years, with changes in lifestyle and dietary structure, the incidence of CRC has increased annually. The symptoms of CRC are typically not obvious at the early stages, and tumors often have metastasized by the time the symptoms become noticeable. This is the main reason for the high mortality rate. Therefore, it is imperative to identify novel diagnostic markers, and to investigate the underlying mechanisms of metastasis in CRC.
Collagen type I α 1 (COL1A1) encodes the pro-α 1 chains of type I collagen, which has a triple helix composed of two α 1 chains and one α 2 chain (2). COL1A1 contains three conservative domains, namely a von Willebrand factor type C (vWFC) domain, a collagen triple-helix repeat and a fibrillar collagen C-terminal domain (COLF) (3) . It was recently found that COL1A1 is associated with a variety of tumor types, and that the expression of COL1A1 was high in tumor tissues and cells (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, the function and mechanism of COL1A1 in CRC have not yet been reported. Therefore, in this study we aimed to detect the expression of COL1A1 in trios of tumor, normal and lymph node tissue samples, as well as to analyze the function and molecular mechanism of COL1A1 in the metastasis of CRC.
Materials and methods
Tissue microarrays and cell lines. Tissue chips, including 20 cases and 60 points, were purchased from Outdo Biotech (Shanghai, China). A total of 20 trios of CRC, adjacent normal, and lymph node tissues were included in the tissue microarrays. The CRC SW480 and SW620 cell lines used in this study were obtained from the ATCC and cultured in RPMI-1640 (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37˚C and 5% CO 2 .
Immunohistochemistry (IHC).
The tissue microarrays were immunostained for COL1A1 as previously described (15) . An antibody against COL1A1 was purchased from Abclone (Cambridge, MA, USA). The COL1A1 immunostaining score was calculated according to the percentage of positively stained tumor cells and the staining intensity. The percentage positivity was scored from 0 to 3, with 0 for <10%, 1 for 10-30%, 2 for 31-50%, and 3 for >50%. The staining intensity was scored from 0 to 3, with 0 for no staining, 1 for weakly stained, 2 for moderately stained, and 3 for strongly stained. were scored in a double-blinded manner. The total score for COL1A1 expression was calculated as the percentage positivity score x the staining intensity score, giving a value ranging from 0 to 9. COL1A1 expression was defined as either 'low' (score 0-4) or 'high' (score 5-9) (16).
Construction of COL1A1-knockdown cell lines and transfection.
The siRNA used to inhibit COL1A1 expression was purchased from GenePharma (Shanghai, China). The nucleotide sequence of the siRNA against COL1A1 was TTG GTG TTG TGC GAT GAC GTG. Cells were transfected with siRNA oligonucleotides and plasmids using Lipofectamine ® 2000 (Invitrogen Thermo Fisher Scientific, Inc.).
RNA extraction and reverse transcription-quantitative PCR (RT-qPCR).
Total RNA was extracted from tissues or cells using TRIzol ® reagent (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's instructions. The reverse transcription of RNA to cDNA was performed with a reverse transcription kit (Takara). RT-qPCR analyses were conducted using SYBR-Green ® (Takara) in triplicate.
Results were normalized to the expression of GAPDH (17) . The primer sequences used for RT-qPCR were as follows: COL1A1 forward, 5'-GAG GGC CAA GAC GAA GAC ATC-3', and reverse, 5'-CAG ATC ACG TCA TCG CAC AAC-3'; GAPDH forward, 5'-GAC TCA TGA CCA CAG TCC ATG C-3', and reverse, 5'-AGA GGC AGG GAT GAT GTT CTG-3'.
Transwell assay. The migration of transfected CRC cells was determined as previously described (18) .
Western blot assay. Proteins were extracted using lysis buffer, and quantified using a Bicinchoninic Acid (BCA) Protein Quantification kit (KeyGen Biotech Co., Ltd., Nanjing, China). Protein lysates were separated via 10% SDS-PAGE and transferred onto a PVDF membrane (Roche, Basel, Switzerland). Subsequently, the membrane was incubated with the specific primary antibodies, followed by the appropriate second antibody. The bands were visualized using a Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, Inc.). Antibodies against COL1A1, p-JNK and MMP9 were purchased from Abclone. Antibodies against Rac1-GTP and RhoA-GTP were purchased from NewEast Biosciences (Malvern, PA, USA).
Statistical analysis. Data was analyzed by SPSS 20.0 Statistical software. Western blot bands were quantified by Image J 1.45 software. Quantitative data was plotted by Graphpad prism 5 software and presented as the mean ± SD of at least 3 independent experiments. The differences between independent experimental groups were tested by using a two-tailed paired Student's t-test. Differences were considered significant if P<0.05: 
Results

COL1A1 is upregulated in CRC and metastatic lymph node tissues.
To investigate the role of COL1A1 in CRC tumorigenesis, the expression levels of COL1A1 protein were detected in trios of CRC tissues, adjacent normal counterparts and paired lymph node tissues from 20 patients using IHC analysis. We observed that COL1A1 protein expression was increased in CRC tumor tissues compared with in the adjacent normal mucosae (P<0.001) (Fig. 1A) . Furthermore, COL1A1 protein expression in metastatic lymph node tissues was higher than that in non-metastatic lymph node tissues (P<0.01) (Fig. 1B) . We further evaluated the prognostic role of COL1A1 in CRC. The data from TCGA showed that the disease-free survival (DFS) of patients with higher COL1A1 expression had worse outcomes than did patients with lower COL1A1 expression (Fig. 1C) (19) .
Knockdown of COL1A1 inhibits CRC cell migration in vitro.
As COL1A1 expression appeared to be associated with metastasis, we evaluated the role of COL1A1 in cell migration. We knocked down COL1A1 using siCOL1A1 in SW480 and SW620 cells (Fig. 2A) . Transwell and wound healing assays were used to determine cell motility; the results revealed that the suppression of COL1A1 could attenuate the migration capabilities of SW480 and SW620 cells when compared with cells transfected with a control vector (Fig. 2B and C) .
COL1A1 promotes WNT/planar cell polarity (PCP) pathway activation.
Through gene set enrichment analysis (GSEA), we analyzed the GSE32323 data and observed that the WNT/PCP signaling pathway was correlated with COL1A1 expression (Fig. 3) (20,21) . The results from the TCGA data analysis also showed that COL1A1is correlated with key genes in the WNT/PCP pathway. The results were calculated using the online web service GEPIA (http://gepia .cancer-pku.cn/index.html) (Fig. 4) (19) . We hypothesized that COL1A1 could modulate Wnt/PCP signaling. To test the hypothesis that COL1A1 serves an important role in activating WNT/PCP signaling, we detected the expression of key mediators in the WNT/PCP pathway, including Rac1-GTP, p-JNK, RhoA-GTP, and the target gene MMP9, all of which are important contributors to tumor cell migration and invasion. We found that the inhibition of COL1A1 decreased the expression of Rac1-GTP, p-JNK, RhoA-GTP and MMP9 (Fig. 5) .
Discussion
Metastasis remains the major cause of death in patients with CRC, though the critical molecular mechanisms underlying tumor metastasis are poorly understood. Prior studies have shown that COL1A1 is upregulated in CRC tissues vs. normal tissues (22) . COL1A1 is a major component of collagen type I. The available reports regarding COL1A1 have mainly focused on osteogenesis, osteoporosis and bone diseases (23) . Recently, many studies have shown COL1A1 to be associated with a variety of tumor types, and that the expression of COL1A1 is increased in tumor tissues and cells (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, little is known about the function and mechanism of COL1A1 in CRC. In this study, we investigated COL1A1 expression in CRC tumor tissues, adjacent normal counterparts and paired lymph node tissues, and explored its function and underlying mechanism in CRC. Compared with the normal tissues, the expression of COL1A1 was increased in CRC tumor tissues and paired lymph node tissues. Moreover, COL1A1 upregulation in patients with CRC indicated poorer outcomes and DFS. These results indicated that COL1A1functions as an oncogene in CRC progression and is associated with metastasis.
To further ascertain the roles of COL1A1 in CRC, we determined the migration ability of cells with reduced-COL1A1 expression. The results showed that the suppression of COL1A1 decreased the migratory ability of CRC cells; therefore, COL1A1 appears to exert an oncogenic effect, promoting migration in CRC.
The mechanism of COL1A1 in promoting CRC migration is still uncertain. Through GSEA, we found that the WNT/PCP signaling pathway was enriched when COL1A1 was expressed at higher levels. Moreover, COL1A1 expression was correlated with key genes in the WNT/PCP pathway. We further determined that COL1A1 could regulate Rac1-GTP, p-JNK, and RhoA-GTP expression. These findings suggest that COL1A1 may activate the WNT/PCP signaling pathway. The Wnt signaling pathway consists of three branches: The canonical Wnt/β-catenin signaling pathway, which activates gene transcription through β-catenin nuclear localization; the Wnt/PCP pathway, which regulates cytoskeletal rearrangements through the activation of JNK by the small G protein; and the Wnt/Ca 2+ pathway, which affects cell adhesion and related gene expression by releasing intracellular Ca 2+ . Among these, the Wnt/PCP pathway is evolutionarily conserved, and carries signals from cell-surface Frizzled and ROR2/RYK co-receptors to the nucleus via Rho GTPases and JNK, processes that are essential for cell migration (24) . Rho GTPases (e.g., Rac1 and RhoA) and JNK are involved in cell morphology, adhesion and metastasis. JNK can rearrange the actin cytoskeleton, thereby regulating the planar polarity of the cell to promote invasion and metastasis of the tumor. JNK can also increase the secretion of MMPs in CRC cells to promote their metastasis (25) (26) (27) . Therefore, we speculated that COL1A1 may promote CRC cell migration through the WNT/PCP pathway.
In summary, our results indicated that COL1A1 promotes tumor metastasis, and that its inhibition may suppress CRC cell migration. In addition, the role of COL1A1 in CRC metastasis seems to be associated with the regulation of the WNT/PCP pathway. Our findings also indicated that COL1A1 may be a promising therapeutic target for CRC.
